Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Rivastigmine Stories

2013-12-26 08:22:57

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022 Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022 SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, "Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the...

2013-11-21 23:19:32

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022. London (PRWEB) November 21, 2013 PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-29 23:21:16

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022. London (PRWEB) October 29, 2013 PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-24 23:18:56

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013 PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains...

2013-10-24 23:04:24

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013 PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-21 23:20:54

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 21, 2013 PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains...

Cognitive Enhancers Not Effect Against Cognitive Impairment
2013-09-17 08:41:15

redOrbit Staff & Wire Reports - Your Universe Online Memory and concentration-improving drugs do not improve cognition or brain function, and may actually cause adverse health effects in people with mild cognitive impairment, according to research in Monday’s edition of the Canadian Medical Association Journal. These medications, which are known as cognitive enhancers, were found to be ineffective in treating patients suffering from mild cognitive impairment, a condition marked by...

2013-06-27 20:22:17

- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ -- The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon® Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease (AD) with Exelon Patch...

2013-06-11 23:19:42

According to BCC Research´s report, Alzheimer's Disease Therapeutics and Diagnostics: Global Markets, the global market for Alzheimer´s disease reached $10.2 billion in 2012, and is expected to decrease at a compound annual growth rate (CAGR) of -1.5% to reach $9.5 billion in 2017. Wellesley, MA (PRWEB) June 11, 2013 Every second a new person in the United Stated develops Alzheimer´s disease. This astonishing statistic has become a reality for the 5.4 million Americans now...

2013-03-08 08:23:37

PARSIPPANY, N.J., March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength. Actavis' ANDA product is a generic version of Novartis' Exelon(®) Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's...